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| INTRODUCTION
One of the main advantages of the direct oral anticoagulants (DOACs) is fixed daily doses eliminating routine laboratory monitoring for optimal dosing. However, there are certain clinical situations where monitoring the DOAC effect on hemostasis can improve patient management. These situations include, but are not limited to: bleeding complications with or without trauma, thromboembolic events while on therapy, and reversal of anticoagulation.
1 Several different laboratory assays have been evaluated for DOAC monitoring, but none are available for routine clinical use in the US. These methods can be classified into the following: (1) Routine coagulations parameters such as prothrombin time (PT), activated partial thromboplastin time (aPTT); (2) Drug specific tests, such as clotting and chromogenic assays calibrated for each DOAC; and (3) Global tests, such as: thrombelastography, and the thrombin generation assay (TGA). 2 Of these, PT and aPTT assays are the most widely available. However, it has been demonstrated that these assays lack sufficient sensitivity and specificity for routine measurement of most DOACs due to variations in the measured effects of the DOAC depending on the assay, the instrument used, and the specific DOAC under evaluation. [3] [4] [5] TGA measures the concentration of thrombin as a function of time in clotting plasma, providing a global physiologic function test of the hemostatic system. 6 TGA is expressed by reporting the following parameters: (1) lag time, the time elapsed between tissue factor initiation and the moment at which 10 nmol L −1 of thrombin is formed, (2) thrombin peak height, the highest concentration of thrombin detected on the thrombin generation curve, and (3) endogenous thrombin potential (ETP), the area under the thrombin generation curve. There are two additional secondary parameters derived from the aforementioned primary parameters: the time to peak, defined as the time from initiation of the test until the thrombin peak height, and velocity index, the slope of the thrombin formation curve, defined as the thrombin peak height divided by the difference between the time to peak and lag time.
The goal of anticoagulation is to reduce the potential thrombin generation in order to decrease the risk of future thromboembolic events. Thus, an assay measuring thrombin generation may have the potential to monitor the effect of anticoagulants such as DOACs. • TGA parameters were measured and correlated to DOAC levels in 10 healthy volunteers after oral intake of DOACs.
• Lag time is the only sensitive TGA parameter across different DOACs, dabigatran, rivaroxaban and apixaban.
• Endogenous thrombin potential had weak correlation with DOAC levels and not suitable as stand-alone parameter.
values. 15 The shortcomings of the abovementioned studies include TGA parameters were predominantly measured at single time point.
If the parameters were measured beyond a single time point, not all TGA parameters were displayed in the publications. ETP appears to be the TGA parameter most often displayed when the TGA is utilized.
The rationale for the use of ETP as compared to the other TGA parameters have not been justified in the reviewed literature, but one can hypothesize that since ETP represents the total bulk coagulability in a sample and is potentially reflective of the thrombotic or bleeding potential in patients.
The purpose of this ex vivo study was to systematically evaluate the anticoagulant effect of dabigatran, rivaroxaban, and apixaban on each individual TGA parameter through serial measurements over time and to establish correlations with the drug concentrations used for standard treatment of atrial fibrillation or venous thromboembolism in order to better define expected alteration of all of TGA parameters after intake of these classes of agents, as well as to demonstrate suitability of these parameters for monitoring the anticoagulant effect of DOACs.
| MATERIALS AND METHODS

| Study design
The study was approved by the local institutional review board and was performed in accordance with the Helsinki declaration. Healthy male volunteers were included in the study. Because female subjects during reproductive age may be subject to unpredictable variation in their coagulation status based on the timing of the blood sampling and menstrual cycle, it is common practice for coagulation studies with small sample sizes to use only male subjects. The rationale for using exclusively male volunteers in our study was to avoid interaction between the aforementioned phenomenon and the true effect of the DOAC agents on coagulation status. Subjects were included if they met the following inclusion criteria: male gender, age between 18 years and 70 years, normal laboratory screening test results, no abnormalities on physical examination, normal vital signs, and the ability to provide written informed consent. Laboratory screening included renal and hepatic function, hepatitis B virus, hepatitis C virus, and HIV serology, a complete blood cell count, PT, and aPTT. The use of aspirin and non-steroidal anti-inflammatories excluded subjects from participation.
The exclusion criteria were as follows: a history of allergic reactions to blood products, a personal or family history of coagulation disorders, participation in any other investigational intervention study within the past 30 days, and any medication use within 7 days before the start of the study. Each subject received a single dose of 150 mg dabigatran, 20 mg rivaroxaban, or 10 mg apixaban at different time points with at least 2 weeks between intakes to allow for a wash out period.
The rationale for the choice of the above-mentioned doses were based on standard recommendations for drug administration at the therapeutic dose, rivaroxaban administered at 20 mg once a daily, dabigatran administered at 150 mg twice daily, and apixaban administered at 5 or 10 mg twice daily based on indication for use (atrial fibrillation vs acute thromboembolism).
Blood samples were obtained at time 0 before intake of the anticoagulant, and subsequently 2, 4, and 24 hours after the drug intake. 
| Thrombin generation
Thrombin generation measurements were performed using the Plasma, Precision BioLogic, Dartmouth, NS, Canada) was used not only as a control on each plate, but also allowed for normalization of the endogenous thrombin potential (ETP) and thrombin peak height data to correct for inter-plate variability.
| Measurement of DOAC concentrations
Plasma was collected from each sample and analyzed using dedicated factor Xa (FXa), which is at a constant concentration and in excess.
The remaining FXa is then measured by its amidolytic activity on FXa specific chromogenic substrate which releases paranitroaniline (pNA).
The amount of pNA generated is inversely proportional to the concen- 
| Statistical analysis
TGA parameters (lag time, thrombin peak height, ETP, time to peak, and velocity index) were correlated to individual DOAC concentrations. Spearman's correlations coefficient r and P values for significance were reported for linear regression models. If the pattern did 
| RESULTS
Ten healthy male volunteers (mean age 41 ± 15 SD, median 37, Among all the TGA parameters, lag time was most strongly correlated with DOAC concentrations and significantly increased at two and four hours after administration across the DOAC classes ( Figure 1B ) (r = .81 for dabigatran, r = .91 for rivaroxaban, r = .83 for apixaban, P < .0001 for all) (Figures 2A, 3A , and 4A). ETP was significantly reduced 2 hours after intake of the FXa inhibitors, rivaroxaban and apixaban ( Figure 1C) , with moderate correlation with the FXa inhibitor levels ( Figures 3B and 4B) . ETP levels demonstrated a decreasing trend over time after intake of dabigatran, but the change was not statistically significant ( Figure 1C ) (ANOVA P = .7). There was a weak but statistically significant correlation, between dabigatran concentration and ETP (r = −.41, P = .02) ( Figure 2B ). Thrombin peak height was significantly decreased at 2 and 4 hours after intake of FXa inhibitors ( Figure 1D ), and showed a strong nonlinear correlation with plasma concentrations fitting exponential decay (R² = .95 for rivaroxaban and R² = .87 for apixaban) ( Figures 3C and 4C ). Thrombin peak height demonstrated no statistically significant trend over time with dabigatran ( Figure 1D ) (ANOVA P = .96). For the FXa inhibitors, the time to peak was significantly increased and the velocity index was significantly decreased at 2 and 4 hours after intake (ANOVA P < .0001
for both FXa inhibitors using both parameters). Both parameters were strongly correlated with FXa inhibitor levels ( Figures 3D, 3E, 4D , and 4E). The pattern of correlation between drug concentrations and velocity index for FXa inhibitors followed exponential decay similar to thrombin peak height. For dabigatran, there were no significant trends over time for time to peak and the velocity index (ANOVA P = .06 for time to peak and P = .96 for velocity index). demonstrate that for the FXa inhibitors, the thrombin peak height appears to display superior correlation to drug concentrations as compared to ETP and other TGA parameters. The correlation exhibited nonlinear exponential decay as a function of drug concentration in accordance to previously published literature. 16 The decay trend reflects diminishing thrombin generation as more FXa active binding sites being occupied by the FXa inhibitor molecules until saturation point is achieved, and where further increase in FXa inhibitor concentration would no longer impact the thrombin generation. Given this observed decaying pattern, the values of thrombin peak height appear to be most predictive of FXa concentrations at lower concentrations of 100 ng mL −1 or lower for rivaroxaban and 150 ng mL −1 or lower for apixaban ( Figures 3C and 4C ). As the velocity index is a product of thrombin peak height divided by a time factor, it is clear that this parameter also exhibits an exponential trend similar and parallel to the thrombin peak height. Dabigatran was poorly correlated with the thrombin peak height and therefore similar mechanism was not observed by use of the TGA technique at the concentrations achieved in the present study.
| DISCUSSION
Currently, specific DOAC assays are available capable of measuring exact drug concentrations for each individual anticoagulant. 8, 17, 18 However, the use of such assays in patient care requires more clini- Even though TGA has favorable correlation with DOAC concentrations, and is commonly applied in research studies on the effect of DOACs on hemostasis, it is labor intensive, and requires expertise similar to other manual assays conducted in clinical and research laboratories. Sample preparation and analysis for TGA assays take approximately 2 hours in experienced laboratories. Therefore, in its current format it is likely not suited for emergencies. It is anticipated that the future upgrade of this technology to be more user friendly and better
The scatter diagrams of TGA parameters, lag time, ETP, thrombin peak height, time to peak, and velocity index against rivaroxaban concentrations. The Spearman correlation coefficient r as well as the regression equations are indicated in the diagrams. ETP, endogenous thrombin potential noted in the present study and previously described, is the interaction of samples containing dabigatran with the internal thrombin calibrator, which inhibits the thrombin activity of this reagent, making the results unreliable. 13 In order to make accurate measurements, baseline samples from a given subject, not containing dabigatran, were used in the calibrator wells. This issue can be a limiting factor in the case of monitoring subjects on maintenance treatment with no prior baseline samples available to adjust the calibration, which is not a concern for samples containing apixaban and rivaroxaban.
Our study was limited by the fact that it was performed on a limited number of healthy volunteers, rather than patients with atrial fibrillation or thromboembolic disease. Other limitations include the use of a single dose of the anticoagulants, rather than repeated doses to achieve steady state drug concentrations. Peak concentrations achieved (162 ng mL −1 for rivaroxaban and apixaban and 73 ng mL itors. Other in vitro and patient studies using TGA have also shown a lack of sensitivity of TGA parameters when dabigatran was used. 2, 7, 8, 21 As in the present study, the observation was noted on post-operative orthopedic patients using prophylactic doses of dabigatran (220 mg once daily) after correcting the thrombin calibrator wells with patients' baseline plasma samples not containing dabigatran by Freyburger and coworkers. 13 Thus, the lack of sensitivity of TGA parameters to dabigatran is unlikely to be related to the interaction between dabigatran and the Thrombin Calibrator. As the subjects in the present study did not achieve adequate dabigatran concentrations, we cannot rule out whether the other TGA parameters beyond lag time would have shown statistically significant alterations had the subjects achieved higher plasma concentrations by receiving higher doses of dabigatran.
In conclusion, TGA lag time was the most sensitive parameter to the effect of the DOACs across the different classes of these F I G U R E 4 The scatter diagrams of TGA parameters, lag time, ETP, thrombin peak height, time to peak, and velocity index against apixaban concentrations. The Spearman correlation coefficient r as well as the regression equations are indicated in the diagrams. ETP, endogenous thrombin potential 
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